Format

Send to

Choose Destination
Angew Chem Int Ed Engl. 2015 Nov 23;54(48):14531-4. doi: 10.1002/anie.201507928. Epub 2015 Oct 5.

An Epitope-Specific Respiratory Syncytial Virus Vaccine Based on an Antibody Scaffold.

Author information

1
Department of Chemistry, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA 92037 (USA).
2
California Institute for Biomedical Research (Calibr), 11119 N. Torrey Pines Road, La Jolla, CA 92037 (USA).
3
Department of Chemistry, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA 92037 (USA). schultz@scripps.edu.
4
California Institute for Biomedical Research (Calibr), 11119 N. Torrey Pines Road, La Jolla, CA 92037 (USA). fwang@calibr.org.

Abstract

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in children. We have generated an epitope-specific RSV vaccine by grafting a neutralizing epitope (F-epitope) in its native conformation into an immunoglobulin scaffold. The resulting antibody fusion exhibited strong binding affinity to Motavizumab, an RSV neutralizing antibody, and effectively induced potent neutralizing antibodies in mice. This work illustrates the potential of the immunoglobulin molecule as a scaffold to present conformationally constrained B-cell epitopes.

KEYWORDS:

RSV vaccine; antibodies; conformations; polypeptides; protein engineering

PMID:
26434555
PMCID:
PMC4715490
DOI:
10.1002/anie.201507928
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center